Mangoceuticals (MGRX) Competitors $2.49 +0.02 (+0.81%) (As of 09:15 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends MGRX vs. MRAI, CCM, OPGN, PMD, BRTX, TOI, OTRK, ATIP, ATPC, and KDLYShould you be buying Mangoceuticals stock or one of its competitors? The main competitors of Mangoceuticals include Marpai (MRAI), Concord Medical Services (CCM), OpGen (OPGN), Psychemedics (PMD), BioRestorative Therapies (BRTX), Oncology Institute (TOI), Ontrak (OTRK), ATI Physical Therapy (ATIP), Agape ATP (ATPC), and Kindly MD (KDLY). These companies are all part of the "healthcare" industry. Mangoceuticals vs. Marpai Concord Medical Services OpGen Psychemedics BioRestorative Therapies Oncology Institute Ontrak ATI Physical Therapy Agape ATP Kindly MD Mangoceuticals (NASDAQ:MGRX) and Marpai (NASDAQ:MRAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, community ranking, institutional ownership, analyst recommendations, dividends and risk. Is MGRX or MRAI more profitable? Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -1,237.00%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mangoceuticals-1,237.00% -138.00% -118.88% Marpai -85.70%N/A -100.23% Does the media prefer MGRX or MRAI? In the previous week, Marpai had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 3 mentions for Marpai and 2 mentions for Mangoceuticals. Marpai's average media sentiment score of 0.30 beat Mangoceuticals' score of -0.24 indicating that Marpai is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mangoceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Marpai 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer MGRX or MRAI? Marpai received 2 more outperform votes than Mangoceuticals when rated by MarketBeat users. CompanyUnderperformOutperformMangoceuticalsN/AN/AMarpaiOutperform Votes266.67% Underperform Votes133.33% Which has preferable earnings & valuation, MGRX or MRAI? Mangoceuticals has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMangoceuticals$730K8.49-$9.21M-$5.79-0.43Marpai$37.15M0.61-$28.75M-$2.64-0.62 Do institutionals & insiders believe in MGRX or MRAI? 56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 39.3% of Mangoceuticals shares are held by insiders. Comparatively, 61.3% of Marpai shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer MGRX or MRAI? Marpai has a consensus target price of $6.00, suggesting a potential upside of 265.85%. Given Marpai's stronger consensus rating and higher possible upside, analysts plainly believe Marpai is more favorable than Mangoceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mangoceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Marpai 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, MGRX or MRAI? Mangoceuticals has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500. Comparatively, Marpai has a beta of 4.69, indicating that its stock price is 369% more volatile than the S&P 500. SummaryMarpai beats Mangoceuticals on 13 of the 17 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Mangoceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGRX vs. The Competition Export to ExcelMetricMangoceuticalshealth & allied services, not elsewhere classified IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.20M$2.14B$5.07B$8.90BDividend YieldN/A7.23%4.99%4.07%P/E Ratio-0.4311.5087.8613.46Price / Sales8.496.081,228.8287.66Price / CashN/A10.1339.5136.27Price / Book0.463.886.946.30Net Income-$9.21M$69.56M$119.12M$225.93M7 Day Performance4.18%-0.74%-1.84%-1.32%1 Month Performance2.47%3.92%-3.65%0.60%1 Year Performance-97.93%-18.29%31.64%26.23% Mangoceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGRXMangoceuticals0.508 of 5 stars$2.49+0.8%N/A-98.1%$6.20M$730,000.00-0.433MRAIMarpai2.0113 of 5 stars$1.64+13.1%$6.00+265.9%+80.2%$22.53M$37.15M-0.62150CCMConcord Medical Services0.3453 of 5 stars$4.35-3.3%N/A-58.6%$18.88M$75.69M0.00970Gap UpOPGNOpGenN/A$1.99+1.5%N/A-55.8%$16.64M$3.42M0.00100News CoveragePMDPsychemedics0.5329 of 5 stars$2.33-0.4%N/A+11.0%$13.72M$22.10M-4.57140BRTXBioRestorative Therapies3.7191 of 5 stars$1.49+6.4%$18.00+1,108.1%-22.2%$10.31M$150,000.00-0.927Analyst RevisionNews CoverageGap UpTOIOncology Institute2.3174 of 5 stars$0.14+2.9%$2.50+1,738.2%-94.1%$10.27M$324.24M0.00660Gap DownOTRKOntrak2.7304 of 5 stars$1.72-6.0%$45.00+2,516.3%-79.4%$7.26M$12.74M0.00250Gap DownATIPATI Physical Therapy0.224 of 5 stars$1.59-7.6%N/A-78.2%$7.01M$699.02M0.005,600ATPCAgape ATP0.013 of 5 stars$1.44+2.9%N/A-92.4%$5.75M$1.43M0.0040KDLYKindly MD0.1582 of 5 stars$0.93+2.2%N/AN/A$5.56MN/A0.00N/AGap Up Related Companies and Tools Related Companies MRAI Alternatives CCM Alternatives OPGN Alternatives PMD Alternatives BRTX Alternatives TOI Alternatives OTRK Alternatives ATIP Alternatives ATPC Alternatives KDLY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mangoceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
